| P/E (FY) | — | Sales (TTM) | $320.3M |
| Earnings (TTM) | -$73.8M | ROE | −5.39% |
| Net Margin | −18.75% | ROIC | −6.76% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −19.53% |
Fulgent Genetics provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. Its clinical diagnostics include molecular and genetic testing, anatomic pathology services such as gastrointestinal pathology, dermatopathology, and hematopathology, oncology tests, and sequencer services for hereditary cancer and reproductive health. Its therapeutic development focuses on cancer drug candidates using a nanoencapsulation and targeted therapy platform, and it operates the Picture Genetics platform.
| Market Cap | $557.8M | Trading Days | 2467 |
| 52W High | 31.04 |
| 52W Low | 13.46 |
| % Off High | −36.73% |
| YTD | −25.24% | 1Y | 11.78% |
| 3Y | −49.42% | 5Y | −78.63% |
| Since incept. (ann.) | 8.05% |
Laboratory Services 100% · Therapeutic Development 0%
| Ann. Volatility (1Y) | 57.64% | Ann. Volatility (3Y) | 47.76% |
| Sharpe (1Y) | 0.48 | Sharpe (3Y) | −0.22 |
| Max Drawdown (1Y) | −55.30% | Max Drawdown (3Y) | −65.59% |
| Beta (3Y, vs SPY) | 0.65 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CSTL | CASTLE BIOSCIENCES INC | $741.9M | — |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.05B | — |
| PSNL | Personalis, Inc. | $1.23B | — |
| BDSX | BIODESIX INC | $206.0M | — |
| CDNA | CareDx, Inc. | $1.83B | — |
| FTRE | Fortrea Holdings Inc. | $1.94B | — |
| GRAL | GRAIL, Inc. | $2.72B | — |
| BLLN | BillionToOne, Inc. | $2.84B | 380.6 |
| XGN | EXAGEN INC. | $105.1M | — |
| SERA | SERA PROGNOSTICS, INC. | $97.7M | — |
| CELC | Celcuity Inc. | $4.06B | — |
| CAI |
| Caris Life Sciences, Inc. |
| $4.41B |
| — |